Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 42 results.
User Information
Export Records
  1. 1.   A selective small-molecule nuclear factor-kappa B inhibitor from a high-throughput cell-based assay for "activator protein-1 hits"
  2. Kang, M. I.; Henrich, C. J.; Bokesch, H. R.; Gustafson, K. R.; McMahon, J. B.; Baker, A. R.; Young, M. R.; Colburn, N. H.
  3. Molecular Cancer Therapeutics. 2009 8(3): 571-581.
  1. 2.   JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells
  2. Yin, Y. M.; Wang, S.; Sun, Y. J.; Matt, Y.; Colburn, N. H.; Shu, Y. Q.; Han, X.
  3. Biomedicine and Pharmacotherapy. 2009 63(6): 429-435.
  1. 3.   Targeting the Activator Protein 1 Transcription Factor for the Prevention of Estrogen Receptor-Negative Mammary Tumors
  2. Shen, Q.; Uray, I. P.; Li, Y. X.; Zhang, Y.; Hill, J.; Xu, X. C.; Young, M. R.; Gunther, E. J.; Hilsenbeck, S. G.; Colburn, N. H.; Chodosh, L. A.; Brown, P. H.
  3. Cancer Prevention Research. 2008 1(1): 45-55.
  1. 4.   Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies
  2. Wei, Q.; Jiang, H.; Matthews, C. P.; Colburn, N. H.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2008 105(50): 19738-19743.
  1. 5.   AP-1 a target for cancer prevention
  2. Matthews, C. P.; Colburn, N. H.; Young, M. R.
  3. Current Cancer Drug Targets. 2007, Jun; 7(4): 317-324.
  1. 6.   Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis
  2. Matthews, C. P.; Birkholz, A. M.; Baker, A. R.; Perella, C. M.; Becky, G. R.; Young, M. R.; Colburn, N. H.
  3. Cancer Research. 2007, Mar; 67(6): 2430-2438.
  1. 7.   Discoidin domain receptor 1 mediates collagen-induced nitric oxide production in J774A.1 murine macrophages
  2. Kim, S. H.; Lee, S.; Suk, K.; Bark, H.; Jun, C. D.; Kim, D. K.; Choi, C. H.; Yoshimura, T.
  3. Free Radical Biology and Medicine. 2007, Feb; 42(3): 343-352.
  1. 8.   Fra-1 a target for cancer prevention or intervention
  2. Young, M. R.; Colburn, N. H.
  3. Gene. 2006, Sep; 379: 1-11.
  1. 9.   Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion
  2. Yang, H. S.; Matthews, C. P.; Clair, T.; Wang, Q.; Baker, A. R.; Li, C. C. H.; Tan, T. H.; Colburn, N. H.
  3. Molecular and Cellular Biology. 2006, Feb; 26(4): 1297-1306.
  1. 10.   Growth arrest-inducing genes are activated in Dbl-transformed mouse fibroblasts
  2. Melani, R.; Sallustio, F.; Fardin, P.; Vanni, C.; Ognibene, M.; Ottaviano, C.; Melillo, G.; Varesio, L.; Eva, A.
  3. Gene Expression. 2006 13(3): 155-165.
  1. 11.   Latent membrane protein 1 encoded by Epstein-Barr virus modulates directly and synchronously cyclin D1 and p16 by newly forming a c-Jun/Jun B heterodimer in nasopharyngeal carcinoma cell line
  2. Song, X.; Tao, Y. G.; Zeng, L.; Deng, X. Y.; Lee, L. M.; Gong, J. P.; Wu, Q.; Cao, Y.
  3. Virus Research. 2005, NOV; 113(2): 89-99.
  1. 12.   Epstein-Barr virus-encoded latent membrane protein 1 modulates cyclin D1 by c-Jun/Jun B heterodimers
  2. Song, X.; Tao, Y. G.; Zeng, L.; Yang, J.; Tang, F. Q.; Lee, L. M.; Gong, J. P.; Wu, Q.; Cao, Y.
  3. Science in China Series C-Life Sciences. 2005, AUG; 48(4): 385-393.
  1. 13.   Cadmium-induced malignant transformation in rat liver cells: role of aberrant oncogene expression and minimal role of oxidative stress
  2. Qu, W.; Diwan, B. A.; Reece, J. M.; Bortner, C. D.; Pi, J. B.; Liu, J.; Waalkes, M. P.
  3. International Journal of Cancer. 2005, APR 10; 114(3): 346-355.
  1. 14.   Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation
  2. Yamashita, M.; Ying, S. X.; Zhang, G. M.; Li, C. L.; Cheng, S. Y.; Deng, C. X.; Zhang, Y. E.
  3. Cell. 2005, APR 8; 121(1): 101-113.
  1. 15.   The nitric oxide prodrug, V-PYRRO/NO, protects against cadmium toxicity and apoptosis at the cellular level
  2. Qu, W.; Liu, J.; Fuquay, R.; Shimoda, R.; Sakurai, T.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P.
  3. Nitric Oxide-Biology and Chemistry. 2005, MAR; 12(2): 114-120.
  1. 16.   Heterodimer formation between c-Jun and Jun B proteins mediated by Epstein Barr virus encoded latent membrane protein 1
  2. Song, X.; Tao, Y. G.; Tan, Y. N.; Lee, L. M.; Deng, X. Y.; Wu, Q.; Cao, Y.
  3. Science in China Series C-Life Sciences. 2005, FEB; 48(1): 70-80.
  1. 17.   Inhibition of melanoma growth and metastasis by ATF2-derived peptides
  2. Bhoumik, A.; Gangi, L.; Ronai, Z.
  3. Cancer Research. 2004, NOV 15; 64(22): 8222-8230.
  1. 18.   Transcriptional regulation of Zic3 by heterodimeric AP-1(c-Jun/c-Fos) during Xenopus development
  2. Lee, S. Y.; Lee, F. S.; Moon, J. S.; Kim, J. I.; Park, J. B.; Lee, J. Y.; Park, M. J.; Kim, J.
  3. Experimental and Molecular Medicine. 2004, OCT 31; 36(5): 468-475.
  1. 19.   NF-kappa B activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NF kappa B regulatory site in autocrine human multiple myeloma cells
  2. Xiao, W. H.; Hodge, D. R.; Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2004, OCT; 3(10): 1007-1017.
  1. 20.   Contribution of JNK, Mek, Mos and PI-3K signaling to GVBD in Xenopus oocytes
  2. Mood, K.; Bong, Y. S.; Lee, H. S.; Ishimura, A.; Daar, I. O.
  3. Cellular Signalling. 2004, MAY; 16(5): 631-642.
  1. 21.   Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms
  2. Hou, D. X.; Kai, K.; Li, J. J.; Lin, S. G.; Terahara, N.; Wakamatsu, M.; Fujii, M.; Young, M. R.; Colburn, N.
  3. Carcinogenesis. 2004 25(1): 29-36.
  1. 22.   Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug
  2. Findlay, V. J.; Townsend, D. M.; Saavedra, J. E.; Buzard, G. S.; Citro, M. L.; Keefer, L. K.; Ji, X. H.; Tew, K. D.
  3. Molecular Pharmacology. 2004 65(5): 1070-1079.
  1. 23.   Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation
  2. Dhar, A.; Hu, J.; Reeves, R.; Resar, L. M. S.; Colburn, N. H.
  3. Oncogene. 2004 23(25): 4466-4476.
  1. 24.   Identification and characterization of a novel Ste20/germinal center kinase-related kinase, polyploidy-associated protein kinase
  2. Nishigaki, K.; Thompson, D.; Yugawa, T.; Rulli, K.; Hanson, C.; Cmarik, J.; Gutkind, J. S.; Teramoto, H.; Ruscetti, S.
  3. Journal of Biological Chemistry. 2003 278(15): 13520-13530.
  1. 25.   Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP- 1 transactivation
  2. Yang, H. S.; Knies, J. L.; Stark, C.; Colburn, N. H.
  3. Oncogene. 2003 22(24): 3712-3720.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel